SG11202007172YA - Methods of treating subjects having diabetes with chronic kidney disease - Google Patents
Methods of treating subjects having diabetes with chronic kidney diseaseInfo
- Publication number
- SG11202007172YA SG11202007172YA SG11202007172YA SG11202007172YA SG11202007172YA SG 11202007172Y A SG11202007172Y A SG 11202007172YA SG 11202007172Y A SG11202007172Y A SG 11202007172YA SG 11202007172Y A SG11202007172Y A SG 11202007172YA SG 11202007172Y A SG11202007172Y A SG 11202007172YA
- Authority
- SG
- Singapore
- Prior art keywords
- diabetes
- methods
- kidney disease
- chronic kidney
- treating subjects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862681391P | 2018-06-06 | 2018-06-06 | |
| PCT/US2019/035789 WO2019236844A1 (en) | 2018-06-06 | 2019-06-06 | Methods of treating subjects having diabetes with chronic kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007172YA true SG11202007172YA (en) | 2020-08-28 |
Family
ID=67253960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007172YA SG11202007172YA (en) | 2018-06-06 | 2019-06-06 | Methods of treating subjects having diabetes with chronic kidney disease |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11266652B2 (en) |
| EP (1) | EP3801542B1 (en) |
| JP (1) | JP2021529728A (en) |
| KR (1) | KR20200130281A (en) |
| CN (1) | CN111918655A (en) |
| AU (1) | AU2019282727A1 (en) |
| BR (1) | BR112020024643A2 (en) |
| CA (1) | CA3102412A1 (en) |
| ES (1) | ES2929994T3 (en) |
| IL (1) | IL279174A (en) |
| MX (1) | MX2020013210A (en) |
| PH (1) | PH12020551159A1 (en) |
| SG (1) | SG11202007172YA (en) |
| TW (1) | TW202015696A (en) |
| WO (1) | WO2019236844A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201924689A (en) | 2017-10-02 | 2019-07-01 | 法商波瑟爾公司 | Methods of treating heart failure with preserved ejection fraction |
| EP3801542B1 (en) | 2018-06-06 | 2022-08-10 | Poxel SA | Methods of treating subjects having diabetes with chronic kidney disease |
| KR20210003786A (en) | 2018-06-14 | 2021-01-12 | 폭셀 | Film-coated tablet containing a triazine derivative for use in the treatment of diabetes |
| WO2021222231A1 (en) * | 2020-04-27 | 2021-11-04 | The Research Institute At Nationwide Children's Hospital | PPARγ AGONISTS FOR TREATMENT OF KIDNEY DISEASE |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3287366A (en) | 1963-12-24 | 1966-11-22 | American Cyanamid Co | Novel 1, 2-dihydro-s-triazines |
| JPS4864088A (en) | 1971-12-13 | 1973-09-05 | ||
| JPS5414986B2 (en) | 1973-10-02 | 1979-06-11 | ||
| IL136339A0 (en) | 1997-12-12 | 2001-05-20 | Abbott Lab | Triazine angiogenesis inhibitors |
| FR2804113B1 (en) * | 2000-01-26 | 2004-06-18 | Lipha | ANIMATED DIHYDRO-1,3,5-TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS |
| FR2853650B1 (en) | 2003-04-10 | 2006-07-07 | Merck Sante Sas | AMINE DEDOUBLING PROCESS USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INSULINO-RESISTANCE SYNDROME |
| WO2005070905A1 (en) | 2004-01-20 | 2005-08-04 | Merck & Co., Inc. | Antidiabetic oxazolidinediones and thiazolidinediones |
| FR2896159B1 (en) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITIZING AGENTS. |
| FR2896161B1 (en) | 2006-01-13 | 2008-04-04 | Merck Sante Soc Par Actions Si | USE OF TRIAZINE DERIVATIVES FOR MANUFACTURING A MEDICAMENT HAVING A HEALING OR ANGIOGENIC EFFECT. |
| FR2896157B1 (en) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SECRETION STIMULATION AGENTS. |
| WO2008069222A1 (en) | 2006-12-05 | 2008-06-12 | Semiconductor Energy Laboratory Co., Ltd. | Plasma display panel and field emission display |
| DE102007054416A1 (en) | 2007-11-13 | 2009-05-14 | Studiengesellschaft Kohle Mbh | Process for the preparation of 3,6-dihydro-1,3,5-triazine derivatives for the treatment of diseases associated with insulin resistance syndrome |
| DE102008007314A1 (en) | 2008-02-02 | 2009-08-06 | Merck Patent Gmbh | Process for the preparation of 3,6-dihydro-1,3,5-triazine derivatives |
| AU2009275963B2 (en) | 2008-07-29 | 2014-07-10 | Poxel | Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization |
| WO2010066901A2 (en) | 2008-12-12 | 2010-06-17 | Poxel | Tetrahydrotriazine compounds for treating diseases associated with ampk activity |
| ES2530223T3 (en) | 2008-12-12 | 2015-02-27 | Poxel S.A.S. | Combination of insulin with triazine derivatives and their use to treat diabetes |
| WO2010109015A1 (en) | 2009-03-26 | 2010-09-30 | Poxel | Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization |
| FR2948027A1 (en) | 2009-07-17 | 2011-01-21 | Merck Sante Sas | DIHYDRO-1,3,5-TRIAZINE AMINO DERIVATIVES FOR THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ISCHEMIA AND / OR REPERFUSION |
| TWI436768B (en) | 2010-06-09 | 2014-05-11 | Poxel | Treatment of type 2 diabetes |
| ES2577930T3 (en) | 2010-06-09 | 2016-07-19 | Poxel | Triazine derivatives to delay the onset of type 1 diabetes |
| PL2646422T3 (en) | 2010-12-01 | 2015-12-31 | Poxel | Separation of triazine derivatives enantiomers using tartaric acid |
| US9211263B2 (en) * | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| AU2013207329B2 (en) * | 2012-01-06 | 2017-10-26 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| CA2812519A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2016077126A1 (en) | 2014-11-10 | 2016-05-19 | Merck Sharp & Dohme Corp. | Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease |
| CN105990398B (en) | 2015-02-16 | 2019-01-11 | 上海和辉光电有限公司 | Organic light emitting diode display and its manufacturing method |
| TW201924689A (en) | 2017-10-02 | 2019-07-01 | 法商波瑟爾公司 | Methods of treating heart failure with preserved ejection fraction |
| EP3801542B1 (en) | 2018-06-06 | 2022-08-10 | Poxel SA | Methods of treating subjects having diabetes with chronic kidney disease |
-
2019
- 2019-06-06 EP EP19739429.9A patent/EP3801542B1/en active Active
- 2019-06-06 ES ES19739429T patent/ES2929994T3/en active Active
- 2019-06-06 AU AU2019282727A patent/AU2019282727A1/en not_active Abandoned
- 2019-06-06 SG SG11202007172YA patent/SG11202007172YA/en unknown
- 2019-06-06 JP JP2020556319A patent/JP2021529728A/en active Pending
- 2019-06-06 MX MX2020013210A patent/MX2020013210A/en unknown
- 2019-06-06 CA CA3102412A patent/CA3102412A1/en active Pending
- 2019-06-06 BR BR112020024643-3A patent/BR112020024643A2/en unknown
- 2019-06-06 KR KR1020207025547A patent/KR20200130281A/en not_active Application Discontinuation
- 2019-06-06 TW TW108119756A patent/TW202015696A/en unknown
- 2019-06-06 CN CN201980015603.XA patent/CN111918655A/en active Pending
- 2019-06-06 WO PCT/US2019/035789 patent/WO2019236844A1/en active Search and Examination
-
2020
- 2020-03-09 US US16/813,436 patent/US11266652B2/en active Active
- 2020-07-30 PH PH12020551159A patent/PH12020551159A1/en unknown
- 2020-12-03 IL IL279174A patent/IL279174A/en unknown
-
2022
- 2022-01-26 US US17/584,601 patent/US20220387437A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111918655A (en) | 2020-11-10 |
| JP2021529728A (en) | 2021-11-04 |
| TW202015696A (en) | 2020-05-01 |
| US11266652B2 (en) | 2022-03-08 |
| US20200215072A1 (en) | 2020-07-09 |
| WO2019236844A1 (en) | 2019-12-12 |
| MX2020013210A (en) | 2021-02-26 |
| US20220387437A1 (en) | 2022-12-08 |
| PH12020551159A1 (en) | 2021-06-07 |
| CA3102412A1 (en) | 2019-12-12 |
| EP3801542A1 (en) | 2021-04-14 |
| IL279174A (en) | 2021-01-31 |
| AU2019282727A1 (en) | 2020-11-26 |
| KR20200130281A (en) | 2020-11-18 |
| ES2929994T3 (en) | 2022-12-05 |
| EP3801542B1 (en) | 2022-08-10 |
| BR112020024643A2 (en) | 2021-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279174A (en) | Methods of treating subjects having diabetes with chronic kidney disease | |
| IL271230A (en) | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | |
| IL264025A (en) | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | |
| PH12018502593A1 (en) | Combinations of linagliptin and metformin | |
| HK1249054A1 (en) | Treatment of chronic graft versus host disease with syk inhibitors | |
| EP3253451A4 (en) | Diagnosis and treatment of chronic pain | |
| EP3386520A4 (en) | Methods of treating an ocular disease or disorder | |
| GB201608781D0 (en) | Non-invasive blood analysis | |
| MA42287A (en) | TREATMENT OF PATIENTS WITH TYPE 2 SUGAR DIABETES | |
| EP3218481A4 (en) | Biomarkers useful in the treatment of subjects having diseases of the eye | |
| SG11202103972SA (en) | Neurological disease treatment with zilucoplan | |
| DE112019001555A5 (en) | BLOOD PUMP | |
| IL253460A0 (en) | Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide | |
| IL291372A (en) | Treatment of chronic granulomatous disease | |
| SI3630164T1 (en) | Dulaglutide for the treatment of chronic kidney disease | |
| ZA201906997B (en) | Methods of diagnosing and treating chronic kidney disease | |
| IL254500A0 (en) | Treatment of type 2 diabetes mellitus patients | |
| EP3600251A4 (en) | Methods of treatment for kidney disease | |
| IL286099A (en) | Methods of treating disease with levoketoconazole | |
| HK1251021A1 (en) | Diagnosis and treatment of mers-related renal disease | |
| EP3273965A4 (en) | Composition and methods for treating chronic kidney disease | |
| GB201811629D0 (en) | Venous disease | |
| GB201804018D0 (en) | Blood pump | |
| EA201892832A1 (en) | COMBINATIONS OF LINAGLIPTINA AND METFORMINA | |
| GB201811912D0 (en) | Treatment of disease |